Market Closed -
Nasdaq
04:15:00 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
17.14
USD
|
+1.96%
|
|
+11.08%
|
-20.13%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,673
|
10,044
|
5,447
|
3,777
|
2,966
|
2,443
|
-
|
-
|
Enterprise Value (EV)
1 |
1,258
|
8,575
|
4,581
|
2,441
|
1,931
|
1,034
|
1,273
|
2,362
|
P/E ratio
|
-8.42
x
|
133
x
|
-18.7
x
|
-10.7
x
|
-20.2
x
|
-6.57
x
|
-6.49
x
|
-7.99
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
62.7
x
|
29.9
x
|
112
x
|
34.8
x
|
8.97
x
|
37.2
x
|
20.1
x
|
9.74
x
|
EV / Revenue
|
47.1
x
|
25.5
x
|
94.1
x
|
22.5
x
|
5.84
x
|
15.7
x
|
10.5
x
|
9.42
x
|
EV / EBITDA
|
-6.13
x
|
120
x
|
-16
x
|
-7.39
x
|
-10.7
x
|
-2.48
x
|
-3.3
x
|
-6.77
x
|
EV / FCF
|
-7.42
x
|
20.8
x
|
-20.8
x
|
-9.3
x
|
-5.21
x
|
-2.9
x
|
-3.39
x
|
-9.62
x
|
FCF Yield
|
-13.5%
|
4.82%
|
-4.8%
|
-10.8%
|
-19.2%
|
-34.4%
|
-29.5%
|
-10.4%
|
Price to Book
|
4.22
x
|
8.78
x
|
5.67
x
|
3.63
x
|
2.86
x
|
2.07
x
|
2.61
x
|
3.12
x
|
Nbr of stocks (in thousands)
|
96,031
|
119,918
|
122,126
|
135,814
|
138,197
|
142,540
|
-
|
-
|
Reference price
2 |
17.42
|
83.76
|
44.60
|
27.81
|
21.46
|
17.14
|
17.14
|
17.14
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/28/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
26.68
|
335.7
|
48.66
|
108.5
|
330.5
|
65.76
|
121.3
|
250.8
|
EBITDA
1 |
-205.2
|
71.25
|
-287.2
|
-330.4
|
-180
|
-416.5
|
-386.1
|
-349
|
EBIT
1 |
-213.2
|
62.72
|
-295.8
|
-340.7
|
-196.7
|
-448.1
|
-445.7
|
-307.8
|
Operating Margin
|
-799.1%
|
18.69%
|
-607.78%
|
-314.16%
|
-59.51%
|
-681.52%
|
-367.45%
|
-122.76%
|
Earnings before Tax (EBT)
1 |
-198
|
71.96
|
-291.2
|
-326
|
-145.2
|
-413.1
|
-435.5
|
-343.8
|
Net income
1 |
-197.6
|
71.14
|
-290.6
|
-326
|
-145.2
|
-409.9
|
-442
|
-337.4
|
Net margin
|
-740.74%
|
21.19%
|
-597.15%
|
-300.56%
|
-43.94%
|
-623.42%
|
-364.34%
|
-134.54%
|
EPS
2 |
-2.070
|
0.6300
|
-2.390
|
-2.600
|
-1.060
|
-2.608
|
-2.640
|
-2.146
|
Free Cash Flow
1 |
-169.5
|
413.1
|
-219.9
|
-262.5
|
-370.9
|
-356.1
|
-375.9
|
-245.5
|
FCF margin
|
-635.34%
|
123.06%
|
-451.88%
|
-242.06%
|
-112.22%
|
-541.63%
|
-309.88%
|
-97.89%
|
FCF Conversion (EBITDA)
|
-
|
579.74%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
580.66%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/28/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
5.285
|
12.51
|
42.14
|
52.48
|
3.559
|
10.28
|
35.14
|
294.1
|
1.267
|
-
|
13.02
|
12.78
|
12.61
|
12.28
|
-
|
EBITDA
1 |
-83.41
|
-75.03
|
-64.42
|
-59.34
|
-105.3
|
-101.3
|
-110.8
|
172.8
|
-
|
-130.4
|
-111.4
|
-100.6
|
-108.4
|
-90.59
|
-
|
EBIT
1 |
-85.59
|
-77.12
|
-66.5
|
-61.42
|
-107.5
|
-105.3
|
-120.8
|
170.5
|
-113.8
|
-132.6
|
-117.8
|
-110.9
|
-113
|
-109.6
|
-
|
Operating Margin
|
-1,619.55%
|
-616.28%
|
-157.8%
|
-117.03%
|
-3,020.12%
|
-1,024.45%
|
-343.8%
|
57.96%
|
-8,981.45%
|
-
|
-904.84%
|
-867.57%
|
-895.64%
|
-892.63%
|
-
|
Earnings before Tax (EBT)
1 |
-84.59
|
-75.84
|
-65.22
|
-58.77
|
-103.3
|
-98.68
|
-109.8
|
183.4
|
-99.35
|
-119.4
|
-108.8
|
-101.5
|
-106.1
|
-108.9
|
-
|
Net income
1 |
-84.59
|
-75.26
|
-65.22
|
-58.79
|
-103.3
|
-98.68
|
-109.8
|
183.4
|
-99.35
|
-119.5
|
-106
|
-101.4
|
-103
|
-106.8
|
-
|
Net margin
|
-1,600.53%
|
-601.41%
|
-154.77%
|
-112.03%
|
-2,902.47%
|
-959.62%
|
-312.4%
|
62.35%
|
-7,841.59%
|
-
|
-813.86%
|
-793.36%
|
-816.14%
|
-869.69%
|
-
|
EPS
2 |
-0.6900
|
-0.6200
|
-0.5300
|
-0.4800
|
-0.8400
|
-0.7500
|
-0.8000
|
1.300
|
-0.7200
|
-0.8600
|
-0.6959
|
-0.6693
|
-0.6757
|
-0.6570
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
2/28/22
|
5/5/22
|
8/8/22
|
11/3/22
|
2/27/23
|
5/8/23
|
8/8/23
|
11/7/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
415
|
1,470
|
865
|
1,336
|
1,035
|
1,409
|
1,170
|
81.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-169
|
413
|
-220
|
-263
|
-371
|
-356
|
-376
|
-245
|
ROE (net income / shareholders' equity)
|
-42%
|
9.2%
|
-27.5%
|
-32.5%
|
-14%
|
-32.4%
|
-34.5%
|
-30.2%
|
ROA (Net income/ Total Assets)
|
-32.5%
|
6.59%
|
-19.3%
|
-22.8%
|
-17.6%
|
-32.9%
|
-38.6%
|
-30.9%
|
Assets
1 |
607.6
|
1,079
|
1,504
|
1,432
|
823
|
1,246
|
1,144
|
1,092
|
Book Value Per Share
2 |
4.130
|
9.550
|
7.870
|
7.670
|
7.500
|
8.290
|
6.560
|
5.490
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-1.950
|
-2.610
|
1.180
|
-0.2500
|
-
|
Capex
1 |
17.9
|
3.1
|
8.5
|
17.8
|
12.9
|
26
|
12.4
|
13.5
|
Capex / Sales
|
67.17%
|
0.92%
|
17.47%
|
16.44%
|
3.91%
|
39.6%
|
10.23%
|
5.38%
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/28/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
17.14
USD Average target price
40.27
USD Spread / Average Target +134.93% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.13% | 2.44B | | -1.43% | 104B | | +8.96% | 105B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|